Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afuresertib with Enzalutamide or Abiraterone in mCRPC
NCT02380313Phase 1Withdrawn
- Sponsor
- GSK
- Start
- Oct 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of afuresertib in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by GSK. Primary endpoints: Number of participants with adverse events, serious adverse events and dose limiting toxicities up to 6 months, Change from baseline in composite of laboratory parameters up to 6 months and 4 more. Planned start Oct 2015; status: withdrawn.
02
Drugs
afuresertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02380313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02380313.